



# Immunization Update

The Iowa Immunization Program Newsletter

CHESTER J. CULVER, GOVERNOR • THOMAS NEWTON, DIRECTOR, IDPH

January 2008

Volume 1, Issue 6

Jim Goodrich, Chief  
Bureau of Disease Prevention and  
Immunization  
•  
Don Callaghan, Manager  
Immunization Program

**Iowa's  
Immunization  
Registry Information  
System (IRIS)  
Enroll Today!**

**Call the IRIS  
Help Desk at  
1-800-374-3958  
for Enrollment Details or  
IRIS Questions.**

**Help Us Help You!**

Is this newsletter helpful to you?  
What articles would you like to see?  
Please contact Bridget Konz at  
bkonz@idph.state.ia.us or  
1-800-831-6293 ext. 7.

**Inside This Issue**

Flumist and the VFC Program	2
Changes to the Adult Schedule	3
CDC Education Update	4
Teens and Vaccines	4
Detour—The Road to VMBIP	5
PedvaxHib HIB Vaccine Availability	5

## It's Not Too Late To Vaccinate!

Remember that December, January, even February is not too late to vaccinate against influenza! In the United States, localized outbreaks that indicate the start of seasonal influenza activity can occur as early as October.

However, in greater than 80% of influenza seasons since 1976, peak influenza activity (which is often close to the midpoint of influenza activity for the season) has not occurred until January or later, and in greater than 60% of seasons, the peak was in February or later.

To avoid missed opportunities for vaccination, providers should offer vaccination during routine health-care visits or during hospitalizations whenever vaccine is available.

Vaccination efforts should continue throughout the season since the duration of the influenza season varies and influenza may not appear in communities until February or March. Providers should offer influenza vaccine routinely, and organized vaccination campaigns should continue throughout the influenza season, including after influenza activity has begun in the community.



Vaccine administered in December or later, even if influenza activity has already begun, is likely to be beneficial in the majority of influenza seasons. The majority of adults will develop antibody protection against influenza virus infection within 2 weeks after vaccination.

Children aged 6 months through 8 years who have not been vaccinated previously or who were vaccinated for the first time during the previous season and received only 1 dose should receive 2 doses of vaccine.

These children should receive their first dose as soon after vaccine becomes available, so both doses can be administered before the onset of influenza activity<sup>1</sup>.

For questions regarding VFC flu vaccine supply and distribution, please contact Tina Patterson at 1-800-831-6293, ext.4; or for medical flu questions, please contact Terri Thornton or Bridget Konz at 1-800-831-6293, ext. 1 and 7 respectively. <sup>1</sup>: MMWR 2007 Jul 13;56(RR06):1-54.



**VACCINE UNIVERSITY**

## Updated Materials

In November, 2007 the Iowa Immunization Program presented Vaccine University to over 500 participants across the state.

The storage and handling binder that was provided as part of the training contains the *Recommendations for Storage and Handling of Selected Biologicals* published by the Centers for Disease Control and Prevention (CDC). This booklet outlines the details of storing and handling of all vaccines. Information includes shipping requirements, condition upon arrival, storage requirements, shelf life, instructions for use, shelf life after opening, and special instructions.

In late November 2007, the CDC updated the *Vaccine Management Book*. An updated copy of this publication can be found at the following CDC webpage:

[http://www.cdc.gov/nip/publications/vac\\_mgt\\_book.htm](http://www.cdc.gov/nip/publications/vac_mgt_book.htm). *Continued on page 2*

## FluMist Influenza Vaccine—Vaccines for Children Program

On September 19, 2007, the U.S. Food and Drug Administration (FDA) approved the expanded use of FluMist (Influenza Virus Vaccine Live, Intranasal) in children two through four years of age. FluMist is now approved for active immunization for the prevention of influenza disease in individuals 2 through 49 years of age.

Prior to inclusion of these recommendations into the Vaccines for Children (VFC) Program, federal law requires the Advisory Committee on Immunization Practices (ACIP) to pass resolutions that determine VFC Program vaccine availability and immunization schedules.

On October 26, 2007, the ACIP voted to include the new licensing for FluMist into the VFC Program. This change allows VFC Program providers can administer FluMist vaccine to eligible children, 2 through 18 years of age.



### VFC Program Recommended LAIV (FluMist) Vaccine Schedule

<u>Age Group</u>	<u>Number of Doses</u>
2 through 18 years of age	1 or 2*

\*All children 2 through 8 years of age who receive LAIV (FluMist) influenza vaccine for the first time should be given two doses. Children who receive only one dose in the first year of vaccination should receive two doses, rather than one, in their second year of vaccination.

### Recommended LAIV (FluMist) Interval (2-8 years of age)


<u>Minimum Age</u>	<u>Minimum interval dose 1 to 2 (when</u>
2 years	4 weeks

If you have questions regarding the above information or the administration of LAIV (FluMist) influenza vaccine please contact Terri Thornton or Bridget Konz at 1-800-831-6293, ext. 1 and 7 respectively.

## Vaccine University Updated Material (cont)

The changes, aside from general word/formatting edits, in the November Publication include:

- (1) TIV: "Protect TIV (Fluairix and FluLaval) from light at all times by storing in the original packages."
- (2) LAIV: "If LAIV is inadvertently frozen, the vaccines should be moved immediately to the refrigerator and may be used until the expiration date stated printed on the package."
- (3) MMRV: "Do not store lyophilized vaccine in the refrigerator. If lyophilized vaccine is inadvertently stored in the refrigerator, it should be used within 72 hours. Lyophilized vaccine stored at 35°F-46°F which is not used within 72 hours should be discarded."
- (4) MPSV: "Multidose vials: Unused portions of multidose vials may be refrigerated at 35°F-46°F and used up to 35 days after reconstitution."



## Cold Weather Shipping Reminder

Please remember that vaccine orders will not be distributed during periods of extreme cold and snow. When outside temperatures drop severely it is possible that even properly packaged vaccine may be exposed to temperatures outside the recommended ranges during the shipping process. If extreme weather prevents shipping, the Immunization Program will notify VFC providers by e-mail. It is important to pay close attention to your vaccine inventory throughout the winter.

Additionally, please remember to return coolers upon receipt of vaccine, using the enclosed postage paid label. If you have questions please contact Janean Iddings at 1-800-831-6293, ext. 5

# Summary of Changes to the Adult Immunization Schedule for 2007-2008

The Advisory Committee on Immunization Practices (ACIP) annually reviews the recommended Adult Immunization Schedule to ensure that the schedule reflects current recommendations for the licensed vaccines. In June 2007, ACIP approved the Adult Immunization Schedule for October 2007–September 2008. The key changes are highlighted below.

### Age-Based Schedule

- The yellow bar for varicella vaccine has been extended through all age groups, indicating that the vaccine is recommended for all adults without evidence of immunity to varicella.
- Zoster vaccine has been added, with a yellow bar indicating that the vaccine is recommended for persons aged >60 years.

### Medical/Other Indications Schedule

- The title has been changed to “Vaccines that might be indicated for adults based on medical and other indications,” indicating that not all of the vaccines are recommended based on medical indications.

- The word “contraindicated” has been added to the red bars and removed from the legend.
- The “immunocompromising conditions” column heading has been shortened by removing the list of conditions.
- The “human immunodeficiency virus (HIV) infection” column has been moved next to the “immunocompromising conditions” column.
- The HIV column has been split into CD4+ T lymphocyte counts of <200 cells/μL and >200 cells/μL.
- The indication “recipients of clotting factor concentrates” has been removed from the column heading “chronic liver disease” because only one vaccine has this recommendation. The indication remains in the hepatitis A vaccine footnote.
- The varicella vaccine yellow bar has been extended to include persons infected with HIV who have CD4+ T lymphocyte counts of >200 cells/μL (1).
- The influenza vaccine yellow bar for “health-care personnel” indicates that health-care

- personnel can receive either trivalent inactivated influenza vaccine (TIV) or live, attenuated influenza vaccine (LAIV).
- The yellow bar for influenza vaccine has been extended to include persons in the “asplenia” risk group.
- The bar for meningococcal vaccine has been revised to indicate that 1 or more doses might be indicated.
- Zoster vaccine has been added to the schedule with a yellow bar to indicate that the vaccine is recommended for all indications except pregnancy, immunocompromising conditions, and HIV. A red bar, indicating a contraindication, has been inserted for pregnancy, immunocompromising conditions, and HIV infection with a CD4+ T lymphocyte count of <200 cells/μL.

Several of the footnotes (numbers 2,3,4,6,9,10, 11, 13) have been reworded or updated. If you have question regarding vaccines or the Adult schedule, please contact Terri Thornton or Bridget Konz at 1-800-831-6293 (ext 2 and 7 respectively).

## Recommended Adult Immunization Schedule

Note: These recommendations must be read with the footnotes that follow.

Figure 1. Recommended adult immunization schedule, by vaccine and age group United States, October 2007 – September 2008

VACCINE ▼	AGE GROUP ▶	19–49 years	50–64 years	≥65 years
Tetanus, diphtheria, pertussis (Td/Tdap) <sup>1,*</sup>		1 dose Td booster every 10 yrs Substitute 1 dose of Tdap for Td		
Human papillomavirus (HPV) <sup>2,*</sup>	3 doses females (0, 2, 6 mos)			
Measles, mumps, rubella (MMR) <sup>3,*</sup>		1 or 2 doses		1 dose
Varicella <sup>4,*</sup>		2 doses (0, 4–8 wks)		
Influenza <sup>5,*</sup>			1 dose annually	
Pneumococcal (polysaccharide) <sup>6,7</sup>		1–2 doses		1 dose
Hepatitis A <sup>8,*</sup>		2 doses (0, 6–12 mos or 0, 6–18 mos)		
Hepatitis B <sup>9,*</sup>		3 doses (0, 1–2, 4–6 mos)		
Meningococcal <sup>10,*</sup>		1 or more doses		
Zoster <sup>11</sup>				1 dose

\*Covered by the Vaccine Injury Compensation Program.

For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g. lack documentation of vaccination or have no evidence of prior infection)

Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)

# CDC Education Updates

## Surveillance of Vaccine-Preventable Diseases (original air date: December 13, 2007).

This course is designed to provide information on case investigation, outbreak control, and disease reporting for vaccine-preventable diseases. The course will stress the most epidemiologically important data to collect and will discuss methods of enhancing surveillance and completing case investigations. The course text is the *Manual for the Surveillance of Vaccine-Preventable Diseases*. This manual is available online only at: <http://www.cdc.gov/vaccines/pubs/surv-manual/default.htm>.


The broadcast will have a live Webcast, which will also be available through the Internet for 1 month following the broadcast and can be found at: <http://www2a.cdc.gov/PHTN/webcast/VPD-07>. This program will be edited and made available for self-study in DVD and web-on-demand formats 4 to 6 weeks after the broadcasts. The program will not be available as a videotape. To order the DVD, use the online order form found at: <http://www.cdc.gov/vaccines/pubs/default.htm>.

Continuing education credits will be provided. For more information, please log on to the National Center for Immunization and Respiratory Diseases and Public Health Training Network Satellite Broadcast & Webcast Program website: <http://www2a.cdc.gov/PHTN/VPD-07>

## Epidemiology and Prevention of Vaccine-Preventable Diseases Satellite Broadcast

The satellite broadcast series Epidemiology and Prevention of Vaccine-Preventable Diseases has been presented at least once a year since 1995. Due to escalating costs and limited availability of the CDC broadcast facility the series will no longer be presented as a live broadcast.

Beginning in 2008 this training program will be available only on DVD and by internet. The 2008 series is expected to be available in late spring. Additional details will be forthcoming in future editions of the Immunization Works newsletter (located at: <http://www.cdc.gov/vaccines/news/newsltrs/imwrks/>)



Adolescents generally seek recommended preventive health services less frequently than children in other age groups and often do not have an identified medical home, making it difficult for health care providers to promote vaccination. Actively encouraging adolescents, teens between the ages of 11 and 19, to be vaccinated is a new focus of the CDC and the Iowa Immunization Program.

The CDC is trying to draw providers and parents focus to the importance of adolescent vaccinations by dividing the recommended childhood and adolescent immunization schedule into two schedules: one for children from birth to six years of age and a second for those seven to 18 years of age, with ages 11-12 recommended for most vaccines. "These new schedules reflect the great strides we are making to protect children and adolescents against serious diseases, including cancer," said Dr. Anne Schuchat, director of the Cen-

ters for Disease Control and Prevention's National Center for Immunization and Respiratory Diseases. "We are providing a separate schedule for those seven to 18 years of age because of an increasing number of vaccines being developed to protect adolescents against disease."

The CDC and the ACIP have recommended three vaccines to be administered to adolescents at the emerging 11-12 year-old "adolescent platform visit." These vaccines include MCV4, which protects against meningitis and its complications; Tdap, which is a booster against tetanus, diphtheria, and pertussis or "whooping cough," and for females, the HPV (Human Papillomavirus) vaccine, which protects against the types of HPV that most commonly cause cervical cancer.

Infant and early childhood immunization programs have grown over the years, which have resulted in record high immunization rates. The Iowa

Immunization Program is working to build and adolescent immunization program that is consistent with the success of the infant program. To assist providers in educating clients, both adolescents and their parents, about the importance of vaccination, the CDC launched a preteen vaccine campaign in August 2007. The campaign materials, including posters and flyers in English and Spanish, are available at the CDC Web site: [www.cdc.gov/vaccines/spec-grps/preteens-adol.htm](http://www.cdc.gov/vaccines/spec-grps/preteens-adol.htm).

If you have questions regarding the Adolescent Immunization Program please contact Kelly Rooney-Kozak at 1-800-831-6293, ext 9.



In previous newsletters we shared Iowa's plans to transition to the Vaccine Management Business Improvement Project (VMBIP) in December. As part of this plan, vaccine in the United States will be shipped from a central location, McKesson General Medical in Memphis, TN.

IDPH Immunization Program has been notified that VMBIP will be delayed until the March 2008. This delay will allow McKesson to complete distribution of influenza products for the states that have already transitioned to VMBIP. In preparation for VMBIP, Iowa has been scaling back vaccine inventory.

Since IDPH has less inventory on hand, it

is imperative that we work together to ensure that clinics have sufficient vaccine available.

Prior to implementing VMBIP in Iowa, the Immunization Program will be working with VFC program providers regarding vaccine ordering schedules and to assess vaccine storage capacity.

Provider's vaccine ordering schedule will be driven by tiered ordering frequency (TOF). TOF refers to establishing vaccine ordering schedule by identifying the number of orders providers should place each year. Transitioning to a monthly, bi-monthly, or quarterly ordering allows IDPH to standardize clinic ordering frequency. TOF will be based on provider ordering volume and IDPH will work with provider to establish an ordering cycle.

In addition to vaccine ordering schedules,

the Iowa VFC Program will be conducting a survey to determine provider storage capacity. The survey will also request office hours to verify when vaccine can be shipped and when the office will be open to receive vaccine shipments.

VFC providers will not see a noticeable difference in the program and will continue to order vaccine either through IRIS or by paper copy. Providers are still required to be accountable for vaccine that has been administered and should ensure that doses are entered into IRIS or accounted for on the Monthly Doses Administered Report. IDPH will continue to share progress and updates regarding the transition to VMBIP.

For questions regarding vaccine distribution, please contact Tina Patterson at 1-800-831-6293, ext. 5.



## Calling All Schools!

The view-only version of IRIS, called the Immunization Registry Information System – Certificate Search (IRIS-CS), is now available.

IRIS-CS allows schools to search, view and print the Certificate of Immunization. Using IRIS-CS will provide schools with required immunization information without added work on behalf of school personnel, parents, and health care providers.

Enroll today! Visit the IRIS Web site to obtain the IRIS-CS enrollment form, computer requirements, and frequently asked questions about IRIS-CS at [www.idph.state.ia.us/adper/immunization\\_programs.asp#iris](http://www.idph.state.ia.us/adper/immunization_programs.asp#iris).

For IRIS-CS questions, please call the IRIS Help Desk at 1-800-374-3958.

## Welcome!

The Immunization Program is happy to announce that Kelly Rooney-Kozac has joined our program as the Adolescent Coordinator. Kelly comes to the Immunization Program from the US Peace Corps where she worked primarily in HIV/AIDS education in the Ukraine.

We are also happy to announce that Kelly and her husband, Roman, welcomed into their family a baby boy on November 29, 2007. We are excited to have her join our team and hope you will welcome her.

Kelly is currently on maternity leave, but when she returns she can be reached at (515) 281-0916, or 1-800-831-6293, ext 8 or by email at: [kr Rooney@idph.state.ia.us](mailto:kr Rooney@idph.state.ia.us).



## Want to receive the Immunization Update Newsletter at your desk?

Do you know someone who would? Send your name, or theirs, and mailing address to [Bkonz@idph.state.ia.us](mailto:Bkonz@idph.state.ia.us) and we will sign you up—it's as easy as that! The Immunization Update is also available on our Web page at: [www.idph.state.ia.us/adper/immunization.asp](http://www.idph.state.ia.us/adper/immunization.asp) It's a great way to send the Newsletter on to others in your facility or community.

## Comments?

We would love to hear what you think of the newsletter, or if there are topics you would like us to cover. Please email Bridget at the email address above.



# PedvaxHIB Vaccine Availability

The Iowa Department of Public Health Immunization Program has received notification from the CDC (CDC) that the supply of haemophilus influenzae B vaccine (Hib) PedvaxHIB manufactured by Merck, is currently unavailable, or in a limited quantities, due to a manufacturing issue.

At this time, Merck is unable to provide information on how long PedvaxHIB will be unavailable. Supply is expected to improve within the first quarter of 2008.

The Immunization Program will fill Hib vaccine orders with ActHIB manufactured by sanofi pasteur. The Immunization Program will continue to review all Hib vaccine orders to assure all providers receive Hib vaccine. It is anticipated that the supply of ActHIB vaccine is sufficient to fulfill Hib vaccine demand during the unavailability of Pedvax-Hib.

All brands of Hib vaccine are interchangeable within their respective series. If brands

are changed during the vaccine series, a 3 dose primary series is required (2, 4, 6 months of age) with a booster (12-15 months of age). After completing the primary series, any Hib conjugate vaccine can be used for the booster dose at

12-15 months of age.

If you have questions regarding vaccine availability please contact Janean at 1-800-831-6293, ext. 5, or for vaccine questions please contact Terri Thornton at 1-800-831-6293, ext 2.

## Hib Vaccine Schedule

**ActHIB (sanofi pasteur):** 3 dose primary series (2, 4, 6 months of age) with a booster (12-15 months of age)

**PedvaxHIB (Merck):** 2 dose primary series (2, 4 months of age) with a booster (12-15 months of age)

### Useful Web Sites for Immunization Providers

Centers for Disease Control and Prevention  
National Immunization Program  
[www.cdc.gov/nip](http://www.cdc.gov/nip)

Iowa Immunization Program  
[www.idph.state.ia.us/adper/immunization.asp](http://www.idph.state.ia.us/adper/immunization.asp)

The Immunization Action Coalition  
[www.immunize.org](http://www.immunize.org)

Children's Hospital of Philadelphia  
[www.vaccine.chop.edu](http://www.vaccine.chop.edu)

American Academy of Pediatrics  
[www.aap.org](http://www.aap.org)

Every Child By Two  
[www.ecbt.org](http://www.ecbt.org)

Food and Drug Administration - Vaccines  
[www.fda.gov/cber/vaccines.htm](http://www.fda.gov/cber/vaccines.htm)

### Ordering Immunization Print Materials On Line!

The Immunization Program has updated our Web page to include on line ordering of all our printed materials. All brochures, posters, and printed documents can be accessed to preview, print single copies, or order multiple copies for your clinic.

Remember that all our printed materials are offered at no cost to your clinic. Our Web page address is:  
[www.idph.state.ia.us/adper/common/pdf/immunization/literature\\_order\\_for\\_m.pdf](http://www.idph.state.ia.us/adper/common/pdf/immunization/literature_order_for_m.pdf).

Materials can still be ordered by phone, fax, and email and general mail. Online ordering is the most recent addition to providing you cost effective, quality print materials.

Call Toll Free 1-888-398-9696, fax your order form to (319) 861-2869, email [clrhhouse@cribrary.org](mailto:clrhhouse@cribrary.org), or mail the order form (which may be found on our Web page) to:

Health Protection Clearinghouse  
615 5th Street SE  
Cedar Rapids, IA 52401

